19 results on atopic dermatitis
To evaluate the additional effect of coal tar treatment to a corticosteroid regimen in adults (aged >16 years of age) with moderate to severe atopic dermatitis, based on the percentage change in Eczema Area and Severity Index (EASI) at week 2…
Primary: To demonstrate the efficacy of QGE031 relative to placebo at 12 weeks in patients withatopic dermatitis (AD) as assessed by Eczema Area and Severity Index (EASI).Secondary: efficacy assessed by Investigator Global Assessment (IGA, 12 weeks…
To determine the functional capacities of regulatory T cells present in lesional and non-lesional atopic dermatitis skin, and lesional and non-lesional psoriasis vulgaris skin.
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…
PrimaryPart 3 - Repeated doses in atopic dermatitis (AD) patients - PDY16891* To evaluate the safety and tolerability of SAR443726 after repeated SC doses in adult participants with moderate-to-severe ADSecondaryPart 3 - Repeated doses in AD…
to investigate whether the levels of a panel of biomarkers in dried blood spots can be used as a disease severity measurement tool in patients with AD, treated with topical steroids.
The two main objectives are the identification of molecular and clinical signatures that can serve as diagnostic and/or severity-of-disease markers for AD in flare and remission. And the identification of key immunological and molecular pathways…
To perform a comprehensive analysis of the cellular infiltrate in lesional AD skin, using state of the art immunohistochemical techniques.
To investigate the therapeutic effect of a selected probiotic mixture on the severity of AD in infants aged 0-15 months. The probiotic mixture has been studied in vitro and has proven IL-10 stimulating effects. Therefore it is thought to decrease AD…
To address the hypothesis that a potato derived protease inhibitor cream significantly limits perianal dermatitis in patients after colorectal surgery.
In this project we will establish primary keratinocyte cell lines of patient skin biopsies from selected skin diseases, to generate 3D skin constructs. In addition, patient DNA will be genotyped for genetic risk factors (psoriasis and AD) or…
To study the impact of primary keratinocytes isolated of allergic contact dermatitis (ACD) cases on THP-1 cell activation.
To assess the long-term safety and tolerability of LOU064 in patients with CSU who have participated in preceding studies with LOU064.
The purpose of this study is to establish efficacy and safety of ligelizumab (QGE031) versus placebo in participants with chronic inducible urticaria who remain symptomatic despite treatment with H1 antihistamine.
Objective: To compare histology, gene expression profile (using transcriptome analysis and quantitative Polymerase Chain Reaction (qPCR) validation) and the microbiome of vesicular endogenous hand eczema between and within patients and to skin of…
Primary objectiveTo assess the efficacy of tildrakizumab treatment (as assessed by PASI 75) in moderate-to-severe plaque psoriasis patients who are non-responders to DMF. Secondary objectivesTildrakizumab- To assess the efficacy of tildrakizumab…
The primary objective of the study is to descriptively characterize the single-dose and steadystatePharmacokinetics (PK) of diacerein (if quantifiable) and its active metabolite, rhein, after topical application of CCP-020 (diacerein 1% ointment)…
Our aim is to optimize treatment for patients with moderate to severe psoriasis by creating evidence for the optimal dose of MTX (on short- and long-term) with the largest disease reduction and the least side effects.
Sub-study APhase 1b:To assess the DLT rate and estimate the MTD of sasanlimab in combination with encorafenib and binimetinib to determine the RP2D for the combination. Phase 2:To assess the durable ORR of sasanlimab in combination with encorafenib…